1. Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162–72.
2. Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085.
3. Amylyx Pharmaceuticals Inc. Amylyx Pharmaceuticals announces Health Canada approval of ALBRIOZA™ for the treatment of ALS [media release]. 13 June 2022. http://www.amylyx.com.
4. Amylyx Pharmaceuticals Inc. ALBRIOZA sodium phenylbutyrate and ursodoxicoltaurine powder for suspension powder for suspension, 3g /1g sachet, oral. 2022. https://health-products.canada.ca/. Accessed 16 July 2022.
5. Amylyx Pharmaceuticals Inc. Amylyx announces support from the ALS Finding a Cure Foundation and the Cure Alzheimers Fund to bring a new treatment for amyotrophic lateral sclerosis to clinical trials [media release]. 17 Nov 2015. http://www.amylyx.com.